The need and total cost of Finnish eyecare services: A simulation model for 2005-2040

Acta Ophthalmologica

Volumn 87, Issue 8, 2009, Pages 820-829

  Tuulonen, Anja ^a   Salminen, Hannu ^b   Linna, Miika ^c   Perkola, Markku ^b  

^a UNIVERSITY OF OULU   (Finland)

^b Systems Thinking Europe Inc   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Access to care; Costs; Healthcare resources; Prioritization; Supply; System dynamics

Indexed keywords

AGING; ARTICLE; CATARACT; CATARACT EXTRACTION; COMPUTER PROGRAM; COMPUTER SIMULATION; DIABETES MELLITUS; DIABETIC RETINOPATHY; EYE CARE; FINLAND; GLAUCOMA; HEALTH CARE ACCESS; HEALTH CARE COST; HOSPITAL BILLING; MATHEMATICAL ANALYSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION;

COMPUTER SIMULATION; FINLAND; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; MODELS, ECONOMIC; MODELS, ORGANIZATIONAL; OPHTHALMOLOGY;

EID: 73349126992     PISSN: 1755375X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2009.01532.x     Document Type: Article

References (38)

1. Bojke L, Claxton K, Sculpher MJ Palmer S (2008 Identifying research strategies: the value of information associated with repeat screening for age-related macular degeneration. Med Decis Making 28 : 33 43.
2. Brommels M, Jouttimäki R-M Myllymäki K (2004 National project to secure the future of health care. Access to health care and waiting list management. Memorandum 2003:33. Helsinki : Ministry of Social Affairs and Health.
3. Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ Price A (2006 Ranibizumab and bevacizumab for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Technology Assessment Report commissioned by the NHS R&D HTA Programme of behalf of the National Institute for Health and Clinical Excellence. http://www.guidance.nice.org.uk/ download.aspx?o=435422
4. Coyle D Drummond M (1995 The economic burden of glaucoma in the UK: the need for a far-sighted policy. PharmacoEconomics 7 : 484 489.
5. European Glaucoma Society (2008 Terminology and guidelines for glaucoma, 3rd edn. Savona, Italy : Editrice Dogma S.r.l.
6. Evans R (1985 Illusion of necessity: evading responsibility for choice in health care. J Health Polit Policy Law 10 : 439 467.
7. Falck A, Tuulonen A, Kuoppala J Winblad I (2008 The Pyhäjärvi Cataract Study. Acta Ophthalmol 86 : 648 654.
8. Forrester JW (1995). The beginning of system dynamics. McKinsey Q 4 : 6 16.
9. Frick KD, Gower EW, Kempen JH Wolff JL (2007 Economic impact of visual impairment and blindness in the United States. Arch Ophthalmol 125 : 544 550.
10. Getzen TE (1992 Population aging and the growth of health expenditures. J Gerontol 47 : 98 104.
11. Grodum K, Heijl A Bengtsson B (2002 A comparison of glaucoma patients identified through mass screening and in clinical routine practice. Acta Ophthalmol Scand 80 : 627 631.
12. Healey P, Tuulonen A The Consensus Group of the World Glaucoma Association (2008 Is the cost of case finding (including diagnosis and treatment of patients diagnosed) economically balanced in relation to possible expenditure on medical care as a whole? The 5th World Glaucoma Association Consensus Meeting, 26 April 2008. Geneva, Switzerland : Geneva Medical Publishers, 40 45
13. Hirvelä H (1995 Visual function and ocular disease in the elderly. The Oulu study. Acta Universitatis Ouluensis Series D Medica 327 : 86s J (2000 Health care into the 21st century. Production and availability of specialised health care services in different parts of Finland in 1999. Working Group Memorandums of the Ministry of Social Affairs and Health, no. 21. Helsinki : Ministry of Social Affairs and Health.
14. Kobelt G (2002 Glaucoma Care Updates. Health economics, economic evaluation, and glaucoma. J Glaucoma 11 : 531 539.
15. Koskinen SV, Reunanen AR, Martelin TP Valkonen T (1998 Mortality in a large population-based cohort of patients with drug-treated diabetes mellitus. Am J Public Health 88 : 765 770.
16. Ministry of Social Affairs and Health (2005). Uniform criteria for access to non-emergency treatment. Helsinki, Finland 2005. Handbook 2005:6 (Enhetliga grunder för icke-brdskande vrd. Social- och hälsovrdsministeriet, ISSN 1236-116X, Handböcker 2005:6)
17. Morley AM Murdoch I (2006 The future of glaucoma clinics. Br J Ophthalmol 90 : 640 645.
18. Muir Gray JA (2001 Evidence-based healthcare. How to make health policy and management decisions. London : Churchill LivingstoneHarcourt Publishers Limited.
19. Mukesh BN, McCarty CA, Rait JL Taylor HR (2002 Five year incidence of openangle glaucoma: the visual impairment project. Ophthalmology 109 : 1047 1051.
20. Newhouse J (1992 Medical care costs: how much welfare loss? J Econ Perspect 6 : 322.
21. Pajunpää H (1999 The costs of photographic screening for diabetic retinopathy and the quality of life and mortality of visually disabled patients. Acta Universitatis Ouluensis Medica 522 : 115s.
22. Palosaari T, Mäkinen E, Kataja M, Räsänen P, Kaila M Uusitalo H (2008 Age-related macular degeneration: what do we know about intravitreous inhibition of angiogenesis? The Finnish Med J 24 : 2229 2236.
23. Punnonen H (2000-2008 Statistics of the hospitals. The Association of Finnish Local and Regional Authorities. 16 April 2008.
24. Raftery J, Clegg A, Jones J, Tan S Lotery A (2007 Ranibizumab (Luncentis) versus bevacizumab (Avastin): modelling cost-effectiveness. Br J Ophthalmol 91 : 1244 1246.
25. Rajala U, Koskela P Keinänen-Kiukaanniemi S (2001 Hyperglycemia as a risk factor on mortality in a middle-aged Finnish population. J Clin Epidemiol 54 : 470 474.
26. Rein DB, Zhang P, Wirth KE et al. (2006 The economic burden of major adult vision disorders in the United States. Arch Ophtahlmol 124 : 1754 1760.
27. SBU Health Technology Assessment (2008) Ranibizumab in treating age-related macular degeneration. http://www.sbu.se/en/Published/Alert/ Ranibizumab-in-treating-agerelated-macular-degeneration/
28. Sterman JD (2000 Business dynamics. Systems thinking and modelling for complex world. Boston : Irwin McGraw-Hill Companies.
29. Sterman J (2002 All models are wrong: reflections on becoming a systems scientist. Syst Dyn Rev 18 : 501 531.
30. Taylor HR, Pezzullo ML Keeffe JE (2006 The economic impact and cost visual impairment in Australia. Br J Ophthalmol 90 : 272 275.
31. Tuulonen A (2003b Can we get rid of waiting lists for cataract surgery? The statistics of eye health care in Finland in 1984-2000 The Finnish Med J 58 : 2657 2663.
32. Tuulonen A (2005 The effects of structures on decision-making policies in health care. Acta Ophthalmol Scand 83 : 611 617.
33. Tuulonen A (2008 The treatment of age-related macular degeneration brings quality and challenges to life. The Finnish Med J 24 : 2219 2220.
34. Tuulonen A Sintonen H (2006 Health economics, cost-effectiveness and glaucoma care. In : Grehn F Stamper R (eds) Glaucoma. Berlin : Springer, 123 133.
35. Tuulonen A, Ohinmaa A, Alanko HI, Hyytinen P, Juutinen A Toppinen E (1999 The application of teleophthalmology in examining patients with glaucoma: a pilot study. J Glaucoma 8 : 367 373.
36. Tuulonen A, Airaksinen PJ, Erola E et al. (2003a The Finnish evidence-based guideline for open-angle glaucoma. Acta Ophthalmol Scand 81 : 3 18.
37. Vaahtoranta-Lehtonen H, Tuulonen A, Aronen P et al. (2007 Cost effectiveness and cost utility of an organized screening programme for glaucoma. Acta Ophthalmol Scand 85 : 508 518.
38. Williams A (1993 Priorities and research strategy in health economics for the 1990s. Health Econ 2 : 295 302.